iSERA Lifesciences Income Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Operating Revenue	13.55	-	-	-	-
Other Revenue	0.14	2.65	-	-	-
Revenue	13.69	2.65	-	-	-
Revenue Growth (YoY)	416.03%	-	-	-	-
Cost of Revenue	4.51	-	-	-	-
Gross Profit	9.18	2.65	-	-	-
Selling, General & Admin	0.57	1.26	0.99	1.16	1.06
Other Operating Expenses	5.81	-	-	-	-
Operating Expenses	6.38	1.26	0.99	1.16	1.06
Operating Income	2.8	1.39	-0.99	-1.16	-1.06
Interest & Investment Income	0.57	-	-	-	-
Other Non Operating Income (Expenses)	-	-	-	-0	-0
EBT Excluding Unusual Items	3.36	1.39	-0.99	-1.16	-1.06
Other Unusual Items	-	-	0.05	0.05	-
Pretax Income	3.36	1.39	-0.94	-1.12	-1.06
Income Tax Expense	0.77	-	-	-	-
Net Income	2.59	1.39	-0.94	-1.12	-1.06
Net Income to Common	2.59	1.39	-0.94	-1.12	-1.06
Net Income Growth	86.62%	-	-	-	-
Shares Outstanding (Basic)	8	0	0	0	-
Shares Outstanding (Diluted)	8	0	0	0	-
Shares Change (YoY)	2525.54%	6.76%	0.09%	-	-
EPS (Basic)	0.31	4.34	-3.14	-3.73	-
EPS (Diluted)	0.31	4.34	-3.14	-3.73	-
EPS Growth	-92.89%	-	-	-	-
Free Cash Flow	-53.54	-14.02	-0.61	-1.23	-3
Free Cash Flow Per Share	-6.37	-43.77	-2.02	-4.12	-
Gross Margin	67.07%	100.00%	-	-	-
Operating Margin	20.44%	52.41%	-	-	-
Profit Margin	18.95%	52.41%	-	-	-
Free Cash Flow Margin	-391.25%	-528.54%	-	-	-
EBITDA	-	-	-	-	-0.07
D&A For EBITDA	-	-	-	-	0.99
EBIT	2.8	1.39	-0.99	-1.16	-1.06
EBIT Margin	20.44%	52.41%	-	-	-
Effective Tax Rate	22.89%	-	-	-	-
Revenue as Reported	14.25	-	-	-	-
Advertising Expenses	0.01	0.05	0.05	0.05	-